A Framework of National Pharmacovigilance System for Developing Countries
Iranian Journal of Pharmaceutical Sciences,
Vol. 20 No. 2 (2024),
23 June 2024
,
Page 169-181
https://doi.org/10.22037/ijps.v20i2.44899
Abstract
Pharmacovigilance is defined as “the science and activities related to the detection, assessment, understanding, and prevention of adverse drug reactions or any other drug-related problems”. The framework of the national pharmacovigilance system illustrates the general pattern of how the health system approaches the care of health products, defines the philosophy of supervision and policy orientation, and outlines the structure and development priorities of pharmacovigilance. The present study was conducted with the aim of presenting a framework of the national pharmacovigilance system framework for developing countries. The present study is of an applied study that was conducted descriptively in 2023. To present a framework of the national pharmacovigilance system framework, the main components of the national pharmacovigilance system framework were first identified and determined through a review of valid scientific sources and texts and national pharmacovigilance systems of the countries under study, considering the conditions and requirements of these countries. Then, the proposed model was put to the opinion of 65 experts for validation, and the Delphi method was implemented with a three-point scale in two rounds. Based on the results of the present study, the main components of the national pharmacovigilance system framework include: functions, infrastructure, and network. Each component includes sub-components and related operations and was agreed upon by experts with an average agreement rate of 95%. The framework of the national pharmacovigilance system is essential as a guide for the implementation of the national pharmacovigilance system. This framework enables a comprehensive evaluation of the structures and national and regional institutions affecting pharmacovigilance and can lead to the optimal implementation of the national pharmacovigilance system in developing countries. The national pharmacovigilance system can reduce drug-related problems, and its ultimate result can be a reduction in mortality and morbidity rates.
- Pharmacovigilance
- Drug monitoring system
- Drug safety
- Adverse drug events
- Adverse drug reactions
How to Cite
References
Campbell J, Gossell-Williams M, Lee M. A review of pharmacovigilance. The West Indian Medical Journal. 2014;63[7]:771.
PI. P. Clinical perspectives in drug safety and adverse drug reactions. Expert Rev Clin Pharmacol. 2008;1[5]:695.
Wiktorowicz M, Lexchin J, Moscou K. Pharmacovigilance in Europe and North America: Divergent approaches. Soc Sci Med. 2012;75[1]:165-170.
World Health Organization. [2004]. Pharmacovigilance: ensuring the safe use of medicines. World Health Organization. https://iris.who.int/handle/10665/68782. [Accessed July, 2021]
Gyllensten H HK, Jönsson AK, Sundell KA, Hägg S, Rehnberg C, et al. Modelling drug-related morbidity in Sweden using an expert panel of pharmacists. Int J Clin Pharm. 2012;34:548.
Santoro A, Genov G, Spooner A, Raine J, Arlett P. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works. Drug Saf. 2017 Oct; 40[10]: 855-869
Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008 Jul; 42[7]: 1017-25.
Brvar M, Fokter N, Bunc M, Mozina M. The frequency of adverse drug reaction related admissions according to method of detection, admission urgency and medical department specialty. BMC Clin Pharmacol. 2009 May 4;9:8.
Hakkarainen KM HK, Petzold M, Hägg S. Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions - a meta-analysis. PLoS One. 2012;7[3]:11-3.
World Health Organization. [2014]. Reporting and learning systems for medication errors: the role of pharmacovigilance centres. World Health Organization. https://iris.who.int/handle/10665/137036. [Accessed May, 2021]
Schatz S, Weber R. Adverse drug reactions. Pharmacy Practice. 2015;1[1].
Watanabe JH MT, Hirsch JD. Cost of Prescription Drug–Related Morbidity and Mortality. Ann Pharmacother. 2018;52[9]:829.
Kant A BJ, Hopkins PM. Adverse Drug Reactions. In Elsevier Inc. 2019:130-143.
Woo SA CA, Wickham ME, Peddie D, Balka E, Scheuermeyer F, et al. Methods for evaluating adverse drug event preventability in emergency department patients. BMC Med Res Methodol. 2018;18[1]:1-8.
Gholami K, Shalviri G. Factors associated with preventability, predictability, and severity of adverse drug reactions. Ann Pharmacother. 1999 Feb; 33[2]: 236-40.
World Health Organization. [2015]. WHO pharmacovigilance indicators: a practical manual for the assessment of pharmacovigilance systems. World Health Organization. https://iris.who.int/handle/10665/186642 [Accessed October, 2022]
Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012 Jun; 91[6]: 1010-21.
World Health Organization. [2002]. The importance of pharmacovigilance. World Health Organization. https://iris.who.int/handle/10665/42493 [Accessed June, 2021]
World Health Organization. [2020]. Action framework to advance universal access to safe, effective and quality-assured blood products 2020–2023. World Health Organization. https://iris.who.int/handle/10665/331002. License: CC BY-NC-SA 3.0 IGO
Rohilla A, Singh N, Kumar V, Kumar M, Sharma AD, Kushnoor A. Pharmacovigilance: Needs and objectives. Journal of Advanced Pharmacy Education & Research Oct-Dec. 2012;2[4].
World Health Organization. Quality Assurance and Safety of Medicines Team. [2006]. The safety of medicines in public health programmes: pharmacovigilance, an essential tool. World Health Organization. https://iris.who.int/handle/10665/43384 [Accessed June, 2021]
Nwokike J LE, Thumm M, An L. Comparative analysis of pharmacovigilance systems in five Asian countries. Pharmacoepidemiol Drug Safety. 2014:23-38.
Olsson S PS, Dodoo A. Pharmacovigilance in resource-limited countries. Expert Rev Clin Pharmacol. 2015;8[4]:449-60.
World Health Organization. [2018]. WHO Drug Information 2018, vol. 32, 2 [full issue]. WHO Drug Information, 32 [2], 187 - 282. World Health Organization. https://iris.who.int/handle/10665/330922 [Accessed Aug, 2021]
Elshafie S RA, Zaghloul I. Pharmacovigilance in developing countries [part II]: a path forward. Int J Clin Pharm. 2018;40[4]:764-8.
Sushma VK AS, SK, S. Pharmacovigilance in India: Present Scenario and Future Challenges. Drug Saf. 2019;42[3]:339-46.
Moscou K, Kohler JC. Pharmacogovernance: Advancing pharmacovigilance and patient safety. In Social and Administrative Aspects of Pharmacy in Low-and Middle-Income Countries. Academic Press: 2018; 403-418.
Strengthening Pharmaceutical Systems [SPS]. Supporting pharmacovigilance in developing countries: the systems perspective. Submitted to the US Agency for International Development by the SPS Program. 2009.
Management Sciences for Health. MDS-3: Managing Access to Medicines and Health.
Technologies. Management Sciences for Health: Arlington, VA [2012].
Saha PS. Starting-up a pharmacovigilance network from scratch: A brief plan. Journal of Pharmaceutical Research and Clinical Practice [JPRCP]. 2014;4[1]:58-66.
Chakrabarty M, Thawani V. Starting a pharmacovigilance center: actions for implementation. Journal of pharmacology & pharmacotherapeutics. 2011;2[4]:295.
Tanja Peters NS, Maya Abbas, Jabeen Ahmad, Jean‑Christophe Delumeau, Esteban Herrero‑Martinez MP, Johanna Piper, Fairouz Smail‑Aoudia, Willemijn van der Spuij TV, Gillian Winstanley Effective Pharmacovigilance System Development: EFPIA‑IPVG Consensus Recommendations. Drug Safety. 2021;44:17-28.
Hamza Y. Garashi DTS, Ellen I. Schafheutle. A Systematic Review of Pharmacovigilance Systems in Developing Countries Using the WHO Pharmacovigilance Indicators. Therapeutic Innovation & Regulatory Science. 2022;56:717-43.
Suke SG, Kosta P, Negi H. Role of pharmacovigilance in India: An overview. Online journal of public health informatics. 2015;7[2].
Jha N, Rathore DS, Shankar PR, Thapa BB, Bhuju G, Alshakka M. Need for involving consumers in Nepal’s pharmacovigilance system. The Australasian medical journal. 2014;7[4]:191.
Sailakshmi BNS LT. Pharmacovigilance for Drug Safety Monitoring. J Pharm Nanotechnol. 2016;4:47-53.
Sumit K AB. HARMACOVIGILANCE IN INDIA: PERSPECTIVES AND PROSPECTS. J Drug Deliv Ther. 2013;3:237-46.
Mustansir MA- SD, Paul S, Rahim Z Bin, Hosen SMZ. Studies on Pharmacovigilance in Bangladesh: Safety Issues. Int J Pharm Teach Pract. 2013:613-21.
Mohiuddin A. Pharmacovigilance: Present Scenario and Future Goals. Indian Journal of Pharmacy Practice. 2019;12.
Strengthening Pharmaceutical Systems [SPS] Program. Indicator-Based Pharmacovigilance Assessment Tool: Manual for Conducting Assessments in Developing Countries. Submitted to the US Agency for International Development by the SPS Program. Arlington [2009[.
Health Mo. Health Product Vigilance Framework. MedEffect TM Canada. 2012.
Brashier DB, Sharma S. An adverse drug reaction clinic: Breathing fresh life into the pharmacovigilance programme. Journal of pharmacology & pharmacotherapeutics. 2012;3[1]:74.
Biswas P, Biswas AK. Setting standards for proactive pharmacovigilance in India: The way forward. Indian Journal of Pharmacology. 2007;39[3]:124.
Sanvidhan G Suke PK, Harsh Negi. Role of Pharmacovigilance in India: An overview. Online Journal of Public Health Informatics. 2015;7[2].
Wangge G, Akbar W. Knowledge, attitudes and practice of pharmacovigilance among health care professionals in Indonesia. Health Science Journal of Indonesia. 2016;7[1]:59-63.
Hartigan-Go K. Developing a pharmacovigilance system in the Philippines, a country of diverse culture and strong traditional medicine background. Toxicology. 2002;181:103-7.
Biswas P. Pharmacovigilance in Asia. Journal of pharmacology & pharmacotherapeutics. 2013;4 [Suppl1]: S7.
Alshammari TM, Alshakka M, Aljadhey H. Pharmacovigilance system in Saudi Arabia. Saudi pharmaceutical journal. 2017;25[3]:299-305.
Elkalmi RM, Hassali MA, Ibrahim MIM, Widodo RT, Efan QM, Hadi MA. Pharmacy students’ knowledge and perceptions about pharmacovigilance in Malaysian public universities. American journal of pharmaceutical education. 2011;75[5].
Shin JY, Jung SY, Ahn SH, Lee SH, Kim SJ, Seong JM, et al. New initiatives for pharmacovigilance in South Korea: introducing the Korea Institute of Drug Safety and risk management [KIDS]. Pharmacoepidemiology and drug safety. 2014;23[11]:1115-22.
- Abstract Viewed: 255 times
- IJPS_Volume20_Issue2_Pages 169-181 Downloaded: 108 times